High glucose promotes gastric cancer chemoresistance in vivo and in vitro

Zhao,Wei; Chen,Rui; Zhao,Mei; Li,Liang; Fan,Lin; Che,Xiang‑Ming

doi:10.3892/mmr.2015.3522

High glucose promotes gastric cancer chemoresistance in vivo and in vitro

Authors:
- Wei Zhao
- Rui Chen
- Mei Zhao
- Liang Li
- Lin Fan
- Xiang‑Ming Che
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Neonatal Surgery, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Department of Pharmacology, College of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: March 20, 2015 https://doi.org/10.3892/mmr.2015.3522
Pages: 843-850
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine whether gastric cancer chemoresistance was increased under high glucose conditions by means of a clinical case study and experimental cytology. The expression of nicotinamide phosphoribosyltransferase (Nampt), silent information regulator 1 (sirt1), p53, p‑glycoprotein (P‑gp) and topoisomerase (topo)‑IIα was evaluated in gastric cancer tissues and gastric cancer with diabetes tissues by immunohistochemistry. Subsequently, the survival time of the patients was assessed. For further investigation, the human gastric cancer cell line SGC7901 was subjected to different glucose concentrations and the aforementioned proteins were detected using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. Finally, cell sensitivity to chemotherapy treatment was examined in order to elucidate the role of high glucose in MDR. Positive expression of Nampt, Sirt1, p53, P‑gp and Topo‑IIα was observed to be higher in gastric cancer with diabetes patients compared with gastric cancer patients (P=0.01, 0.003, 0.0025, 0.016 and 0.336, respectively) with reduced survival time. Similar results were observed in SGC7901 cells. Additionally, cell proliferation rates of SGC7901 cells increased at glucose concentrations of 4,500 and 9,000 mg/l. Notably, the inhibition rates of 5‑fluorouracil on cells decreased over 48 h when treated with 4,500 and 9,000 mg/l glucose compared with 1,000 mg/l. In conclusion, patients suffering from gastric cancer and diabetes exhibited greater negative effects, such as a poorer response to chemotherapy and had a lower survival time. High glucose conditions promoted gastric cancer cell proliferation and reduced susceptibility to chemotherapy drugs. These data provided a potential diagnostic and therapeutic strategy for gastric cancer chemoresistance.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
2	Hartgrink HH, Jansen EP, van Grieken NC, et al: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar : PubMed/NCBI
3	Zhang D and Fan D: New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 6:527–537. 2010. View Article : Google Scholar : PubMed/NCBI
4	Azoulay L, Yin H, Filion KB, et al: The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 344:e36452012. View Article : Google Scholar : PubMed/NCBI
5	Richardson LC and Pollack LA: Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2:48–53. 2005. View Article : Google Scholar : PubMed/NCBI
6	Garten A, Petzold S, Körner A, et al: Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 20:130–138. 2009. View Article : Google Scholar :
7	Feng YH, Velazquez-Torres G, Gully C, et al: The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med. 15:825–836. 2011. View Article : Google Scholar
8	Chiarugi A, Dölle C, Felici R, et al: The NAD metabolome - a key determinant of cancer cell biology. Nat Rev Cancer. 12:741–752. 2012. View Article : Google Scholar : PubMed/NCBI
9	Bi TQ and Che XM: Nampt/PBEF/visfatin and cancer. Cancer Biol Ther. 10:119–125. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bi TQ, Che XM, Liao XH, et al: Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol Rep. 26:1251–1257. 2011.PubMed/NCBI
11	Burger H, Foekens JA, Look MP, et al: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 9:827–836. 2003.PubMed/NCBI
12	Bajrami I, Kigozi A, Van Weverwijk A, et al: Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol Med. 4:1087–1096. 2012. View Article : Google Scholar : PubMed/NCBI
13	Cha EJ, Noh SJ, Kwon KS, et al: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res. 15:4453–4459. 2009. View Article : Google Scholar : PubMed/NCBI
14	Feng AN, Zhang LH, Fan XS, et al: Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int J Surg Pathol. 19:743–750. 2011. View Article : Google Scholar : PubMed/NCBI
15	Imai S: Dissecting systemic control of metabolism and aging in the NAD World: the importance of SIRT1 and NAMPT-mediated NAD biosynthesis. FEBS Lett. 585:1657–1662. 2011. View Article : Google Scholar : PubMed/NCBI
16	Patel ST, Mistry T, Brown JE, et al: A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides. 31:51–57. 2010. View Article : Google Scholar
17	Tanigawa N and Fujii H: Detection of P-glycoprotein and its clinical significance. Nihon Rinsho. 55:1064–1068. 1997.In Japanese. PubMed/NCBI
18	Ezoe S: Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health. 9:2444–2453. 2012. View Article : Google Scholar : PubMed/NCBI
19	Alagoz M, Gilbert DC, El-Khamisy S, et al: DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr Med Chem. 19:3874–3885. 2012. View Article : Google Scholar : PubMed/NCBI
20	Karim S and Ali A: Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World J Gastroenterol. 15:1381–1387. 2009. View Article : Google Scholar : PubMed/NCBI
21	Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science. 253:49–53. 1991. View Article : Google Scholar : PubMed/NCBI
22	Renehan AG, Yeh HC, Johnson HA, Wild SH, Gale EA and Møller H: Diabetes and Cancer Research Consortium: Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 55:1619–1632. 2012. View Article : Google Scholar : PubMed/NCBI
23	Colmers IN, Bowker SL, Tjosvold LA, et al: Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. 38:485–506. 2012. View Article : Google Scholar : PubMed/NCBI
24	Vigneri P, Frasca F, Sciacca L, Pandini G and Vigneri R: Diabetes and cancer. Endocr Relat Cancer. 16:1103–1123. 2009. View Article : Google Scholar : PubMed/NCBI
25	Shikata K, Ninomiya T and Kiyohara Y: Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 104:9–14. 2013. View Article : Google Scholar
26	Li HJ, Che XM, Zhao W, et al: Diet-induced obesity potentiates the growth of gastric cancer in mice. Exp Ther Med. 4:615–620. 2012.PubMed/NCBI
27	Paschou P, Kukuvitis A, Yavropoulou MP, et al: Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population. Cytokine. 51:25–27. 2010. View Article : Google Scholar : PubMed/NCBI
28	Imai S: The NAD World: a new systemic regulatory network for metabolism and aging - Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys. 53:65–74. 2009. View Article : Google Scholar :
29	Yi J and Luo J: SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta. 1804:1684–1689. 2010. View Article : Google Scholar : PubMed/NCBI
30	Zhu H, Xia L, Zhang Y, et al: Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression. PLoS One. 7:e314312012. View Article : Google Scholar : PubMed/NCBI
31	Liang XJ, Finkel T, Shen DW, Yin JJ, Aszalos A and Gottesman MM: SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res. 6:1499–1506. 2008. View Article : Google Scholar : PubMed/NCBI
32	Menssen A, Hydbring P, Kapelle K, et al: The c-MYC oncop-rotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci USA. 109:E187–E196. 2012. View Article : Google Scholar
33	Kojima K, Ohhashi R, Fujita Y, et al: A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun. 373:423–428. 2008. View Article : Google Scholar : PubMed/NCBI
34	Fujita Y, Kojima K, Hamada N, et al: Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 377:114–119. 2008. View Article : Google Scholar : PubMed/NCBI
35	de Figueiredo-Pontes LL, Pintão MC, Oliveira LC, et al: Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin Cytom. 74:163–168. 2008. View Article : Google Scholar : PubMed/NCBI